We report a unique case of brucellosis transmitted by BMT. An 8-year-old boy with the diagnosis of Fanconi's anemia received an allogeneic BMT from his HLAidentical sibling. Routine culture from the infused marrow suspension grew Brucella abortus on day +4 post BMT. Spiking fevers occurred on days +2 and +16. The first febrile episode responded to broad-spectrum antibiotic therapy. However, the second episode did not. B. abortus was isolated from blood cultures taken during the second febrile episode. The Brucella agglutination titer was negative. Antibiotic therapy with oral doxycycline and i.v. gentamycin was successful with no recurrence of infection during 13 months of follow-up. The donor's blood culture was also positive for B. abortus and Brucella antibodies were detectable at 1:320 titer when he presented with fever and hepatosplenomegaly on day +32. We emphasize the need to consider brucellosis in patients undergoing BMT. We suggest that donor and recipient be evaluated for brucellosis especially in countries where the incidence of this infection is relatively high. Bone Marrow Transplantation (2000) 26, 225-226. Keywords: brucellosis; bone marrow transplantation; infection Brucellosis continues to be an important health problem worldwide, mainly in the Mediterranean area and in developing countries. It is primarily a zoonotic infection which can be transmitted to humans through direct contact with infected animals and through consumption of unpasteurized milk or milk products. Human to human transmission of brucellosis is extremely rare. Transmission of Brucella by blood transfusion has been described, 1,2 however, there are no reports in the literature concerning brucellosis occurring in a recipient of bone marrow transplantation. A patient who received bone marrow cells containing Brucella melitensis has been reported, although brucellosis in this recipient could not be demonstrated. 3 We report the case of a patient with bacteriologically documented brucellosis transmitted by BMT. 
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Case report
An 8-year-old boy with Fanconi's anemia received an allogeneic BMT from his HLA-identical brother. Conditioning consisted of oral busulphan 6 mg/kg/total dose for 4 days and intravenous cyclophosphamide 40 mg/kg/total dose for 4 days. Since there was a bidirectional ABO incompatibility, bone marrow was infused after RBC and plasma depletion. The nucleated cell dose of marrow was 2 × 10 8 /kg. A routine culture was sent from the bone marrow suspension. Selective gut decontamination with ciprofloxacin and fluconazole was administered during neutropenia. Graft-versus-host disease (GVHD) prophylaxis was cyclosporin A 3 mg/kg/day i.v. and methotrexate 5 mg/kg i.v. for three doses after transplant. An absolute neutrophil count (ANC) of over 500/mm 3 occurred on day +11, and a platelet count of over 20 000/mm 3 on day +28. Grade I acute GVHD occurred on day +28.
The early post-transplant course was complicated by fever that developed on day +2. Broad-spectrum antibiotic therapy with meropenem was started and the fever subsided within 2 days. On day +4 post BMT, the routine culture of the infused bone marrow was reported positive for Brucella species. Specific therapy for Brucella infection was not initiated at this time. On day +16, the recipient developed chills and fever of 39.5°C; physical examination was unremarkable. In addition to meropenem, vancomycin was started with no improvement. Laboratory studies revealed a drop in ANC to 210/mm 3 , and an increase in liver enzymes (ALT: 278 U/l, AST: 283 U/l) within 3 days of fever. On day +19, blood cultures taken during febrile episodes started to grow Brucella species which was later typed as B. abortus type III. The patient was then treated with oral doxycycline (4 mg/kg/day) and i.v. gentamycin (7 mg/kg/day). Improvement was dramatic and the fever disappeared 3 days later. The liver enzymes started to decline 6 days later and normalised on day +33. All blood cultures taken on days +16, +17, +18 and +19 were positive for B. abortus. Serum antibodies to Brucella were found to be negative by serum agglutination and complement fixation tests. Gentamycin was given for a total of 2 weeks and doxycycline for 8 weeks. The patient is now 13 months post BMT with complete hematopoietic recovery and no evidence of recurrence of Brucella infection.
The donor was a 3.5-year-old boy who did not have any signs or symptoms of brucellosis when he donated his marrow. We aimed to re-evaluate the donor after the result of positive bone marrow culture. However, this was not poss-ible as the family lived far from the BMT center. The donor returned when he had symptoms of fever and malaise on day +32 post BMT. Physical examination showed mild hepatosplenomegaly and the liver enzymes were found to be moderately elevated. His Brucella agglutination titer was 1:320 and blood culture grew B. abortus. Antibiotic therapy with oral trimethoprim-sulfamethoxazole and rifampin was started with good response. The source of brucellosis was identified as fresh unpasteurized cow's milk cheese which was eaten only by the donor approximately 4-6 weeks before the BMT. This cheese had then been kept in salt for 8-10 weeks before it was eaten by the rest of the family members except the recipient. The parents and two other siblings were investigated for Brucella infection and none of them had any clinical or serological evidence of brucellosis.
Discussion
Human to human transmission of brucellosis has been rarely reported. 4 In the literature, there is only one case report about the transmission of brucellosis by BMT. 3 In this report the patient received a marrow suspension containing B. melitensis. However, acquired brucellosis could not be demonstrated in this recipient. In our case, the patient received marrow cells containing B. abortus and developed a clinical picture which was consistent with brucellosis on day +16 post BMT. The diagnosis of brucellosis was made by isolation of B. abortus from blood cultures.
Brucellosis is a zoonotic infection, transmitted to humans primarily by consumption of unpasteurized milk or milk products. The identified source of brucellosis in the donor was the raw cow's milk cheese consumed approximately 5 weeks before BMT. We also considered the transmission of brucellosis to the recipient by the same source before BMT, but the parents clearly pointed out that the donor was the only person in the family who ate the infected cheese before it was salted for preservation. When the parents and two other siblings were investigated, none of them had clinical or serological evidence of brucellosis. Additionally, negative Brucella serology and negative blood cultures taken from the recipient before BMT also supported that the only source of brucellosis in the recipient was bone marrow suspension.
The treatment of brucellosis still presents problems because relapse is relatively frequent, especially when the disease is caused by B. melitensis. 5 Although oral doxycycline given for 3-6 weeks plus intramuscular gentamicin given for the initial 5 days is recommended therapy for children older than 8 years of age, 6 no data exist in the literature concerning appropriate regimen and duration of therapy for brucellosis in immunocompromised patients. We treated our patient for a longer period of time than the standard recommendations and observed no evidence of relapse during 13 months follow-up.
We emphasize the need to consider rare diseases such as brucellosis in patients undergoing bone marrow transplantation especially in developing countries. We believe that both donor and recipient should be evaluated for brucellosis before BMT in countries where the incidence of brucellosis is relatively high.
